Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research by Gassmann, Dimitri et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Liver Allograft Failure After Nivolumab Treatment-A Case Report With
Systematic Literature Research
Gassmann, Dimitri; Weiler, Stefan; Mertens, Joachim C; Reiner, Cäcilia S; Vrugt, Bart; Nägeli, Mirjam;
Mangana, Joanna; Müllhaupt, Beat; Jenni, Fabienne; Misselwitz, Benjamin
Abstract: Background Orthotopic liver transplantation (OLT) is a potential curative treatment in patients
with hepatocellular carcinoma (HCC); however, treatment options for recurrent HCC after OLT are
limited. Immune checkpoint inhibitors, such as nivolumab, an inhibitor of programmed cell death protein
1, have been successfully used for metastatic HCC but data on safety of nivolumab following solid organ
transplantation are limited. Methods We report a 53-year-old woman with HCC who was treated with
OLT. After 2 years, HCC recurred. Initial treatment with sorafenib was discontinued due to side effects
and disease progression. Progressive HCC in the lung and lymph nodes was subsequently treated with
nivolumab. One week after the first nivolumab dose, rapid progressive liver dysfunction was noted.
Liver biopsy revealed severe cellular graft rejection prompting treatment with intravenous steroids and
tacrolimus. Liver function continued to decline, leading to severe coagulopathy. The patient succumbed to
intracranial hemorrhage. Results A systematic PubMed search revealed 29 cases treated with a checkpoint
inhibitor following solid organ transplantation. Loss of graft was described in 4 (36%) of 11 cases with
OLT and in 7 (54%) of 13 cases after kidney transplantation. However, cases with favorable outcome
were also described. Eighteen cases with adverse events were identified upon searching the World Health
Organization database VigiBase, including 2 cases with fatal outcome in liver transplant recipients due
to graft loss. Conclusion Experience with checkpoint inhibitors in solid organ transplant recipients is
limited. Published cases so far suggest severe risks for graft loss as high as 36% to 54%.
DOI: https://doi.org/10.1097/TXD.0000000000000814
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-157309
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Gassmann, Dimitri; Weiler, Stefan; Mertens, Joachim C; Reiner, Cäcilia S; Vrugt, Bart; Nägeli, Mirjam;
Mangana, Joanna; Müllhaupt, Beat; Jenni, Fabienne; Misselwitz, Benjamin (2018). Liver Allograft Fail-
ure After Nivolumab Treatment-A Case Report With Systematic Literature Research. Transplantation
Direct, 4(8):e376.
DOI: https://doi.org/10.1097/TXD.0000000000000814
2
Liver Allograft Failure After Nivolumab
Treatment—A Case Report With Systematic
Literature Research
Dimitri Gassmann, MMed,1 Stefan Weiler, MD, PhD,2 Joachim C. Mertens, MD,3 Cäcilia S. Reiner, MD,4
Bart Vrugt, MD, PhD,5 Mirjam Nägeli, MD,6 Joanna Mangana, MD,6 Beat Müllhaupt, MD,3
Fabienne Jenni, MD,1 and Benjamin Misselwitz, MD3
Background. Orthotopic liver transplantation (OLT) is a potential curative treatment in patients with hepatocellular carcinoma
(HCC); however, treatment options for recurrent HCC after OLT are limited. Immune checkpoint inhibitors, such as nivolumab,
an inhibitor of programmed cell death protein 1, have been successfully used for metastatic HCC but data on safety of nivolumab
following solid organ transplantation are limited.Methods.We report a 53-year-old womanwith HCCwhowas treatedwith OLT.
After 2 years, HCC recurred. Initial treatment with sorafenib was discontinued due to side effects and disease progression. Pro-
gressive HCC in the lung and lymph nodes was subsequently treated with nivolumab. One week after the first nivolumab dose,
rapid progressive liver dysfunction was noted. Liver biopsy revealed severe cellular graft rejection prompting treatment with intra-
venous steroids and tacrolimus. Liver function continued to decline, leading to severe coagulopathy. The patient succumbed to
intracranial hemorrhage. Results. A systematic PubMed search revealed 29 cases treated with a checkpoint inhibitor following
solid organ transplantation. Loss of graft was described in 4 (36%) of 11 cases with OLTand in 7 (54%) of 13 cases after kidney
transplantation. However, cases with favorable outcome were also described. Eighteen cases with adverse events were identified
upon searching the World Health Organization database VigiBase, including 2 cases with fatal outcome in liver transplant recipi-
ents due to graft loss.Conclusion.Experiencewith checkpoint inhibitors in solid organ transplant recipients is limited. Published
cases so far suggest severe risks for graft loss as high as 36% to 54%.
(Transplantation Direct 2018;4: e376; doi: 10.1097/TXD.0000000000000814. Published online 20 July, 2018.)
Hepatocellular carcinoma (HCC) frequently occurs in pa-tients with liver cirrhosis. In selected cases, orthoto-
pic liver transplantation (OLT) is the best curative option.
Hepatocellular carcinoma recurs in about 16%1,2 of patients
after OLT. If OLT is not an option, therapeutic options
for HCC recurrence include the tyrosine kinase inhibitor
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sorafenib.3 Sorafenib has also been used for patients after
OLT, but the therapeutic benefit has not been clearly estab-
lished.4 Usage of sorafenib is in addition limited due to severe
side effects, including hand-foot syndrome, nausea, emesis
and wasting in a large percentage of patients.3,5
Recently, checkpoint inhibitors have been introduced for
immune activation in patients withmetastatic cancer, resulting
in tumor regression and even remission in a subgroup of pa-
tients.6 Nivolumab, an inhibitor of programmed cell death
protein 1 (PD-1), was successfully established as first or sec-
ond line treatment in various malignancies, such as mela-
noma, squamous cell skin carcinoma, non–small-cell lung
carcinoma, kidney carcinoma, and classical Hodgkin lym-
phoma.7 Case series also demonstrate benefits of nivolumab
in HCC on an off-label basis.8 However, solid organ trans-
plant recipients were excluded from checkpoint inhibitor reg-
istration and there is limited experience with the application
of nivolumab in this patient population.9,10 We here present
a case of fulminant liver transplant failure with cellular rejec-
tion and fatal outcome in a patient treated with nivolumab
for recurrent HCC.
MATERIALS AND METHODS
Patient's relatives provided written informed consent to
publication.
We performed a systematic Pubmed literature search with
the following complementary search strategies (February 22,
2018): (nivolumab OR ipilimumab OR pembrolizumab OR
atezolizumab) AND (transplantationOR transplant OR rejec-
tion) yielding 210 publications; (pd-1 AND checkpoint inhib-
itor) AND (organ transplant recipient OR transplantation)
yielding 53 publications; Immune checkpoint inhibitor AND
liver transplant yielding 13 publications. All identified publica-
tions were screened and redundant reports were excluded.
Publications describing patients after solid organ transplanta-
tion treated with 1 or a combination of the 4 checkpoint inhib-
itors, nivolumab, ipilimumab, pembrolizumab, or atezolizumab
with sufficient information regarding the outcome for the
transplanted organ were included. Altogether, our literature re-
search identified 25 publications with 29 cases. The final list is
provided in Table 1.
We searched for individual case safety reports (ICSRs) in the
World Health Organization (WHO) global database VigiBase.
In this database, spontaneously reported adverse drug reactions
are collected as ICSR.We included all ICSRswith the substances,
nivolumab, ipilimumab, pembrolizumab, or atezolizumab
and the reactions “transplant rejection”, “graft rejection”
as a preferred term, low-level term or high-level term re-
ported in the database until August 6, 2017 (total number
of ICSRs 15160.275). Matching of patients from VigiBase
to case reports in Table 1 was not possible and potentially re-
dundant cases could not be excluded.
Case Presentation
A 53-year-old woman of central African origin received
domino-liver transplantation 36 months ago for HCC that
developed on the basis of liver cirrhosis due to chronic hepa-
titis C. Immunosuppression after OLT included prednisone
for 3 months on a tapering scheme, mycophenolate mofetil
(MMF) 1 to 2 g/d for 3 months and everolimus 1 mg/d. In
4 posttransplant biopsies within the first 5 months no rejec-
tion was shown. Hepatitis C virus was successfully treated7
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with sofosbuvir 400 mg/ledipasvir 90 mg for 12 weeks. Two
years after OLT, HCC recurred with pulmonary, pulmonary
bihilar and retroperitoneal lymph node metastases. The pa-
tient received sorafenib for 2 months but stopped the treatment
due to intolerable nausea, emesis, and tumor progression. No
hepatic recurrences could be detected. After thorough discus-
sion of benefits and potential adverse drug reactions—
including risk of graft loss and fatal outcome—treatment with
nivolumab was initiated. A change of immune suppression
was not performed because a recent randomized controlled
study failed to show survival benefits upon sirolimus treatment
for patients with HCC treated after transplantation.36 After ad-
ministration of a single dose of 200 mg nivolumab (3 mg/kg
body weight), an increase in liver function tests was noted
1 week after administration (Figure 1). Liver biopsy was per-
formed 2 weeks after administration of nivolumab and demon-
strated acute cellular transplant Rejection Activity Index
(RAI) 7 (Figure 2) under immunosuppression with everoli-
mus (trough level, 3.3 μg/L) and MMF. Intravenous high-
dose steroid therapy (methylprednisolone 500 mg daily) for
5 days was administered but liver function tests continued
to increase. Steroids were changed to prednisone 40 mg per
day orally and tacrolimus 6 mg per day (aiming for a trough
level of 5 μg/L) was added. No antiplatelet agent and only
prophylactic anticoagulation with subcutaneous low molec-
ular weight heparin was used.
Over the next 3 days, the patient's condition continued to
deteriorate with tiredness, severe nausea and emesis, diffuse
upper abdominal pain, night sweats, alcoholic stools, dark
urine, scleral icterus but no signs of neurological dysfunction.
The patient was admitted to the hospital. Laboratory tests re-
vealed a rapid increasing of liver enzymes (aspartate aminotrans-
ferase, 9347 U/L; norm, <35 U/L; alanine aminotransferase,
6730 U/L; norm, <35 U/L), signs of coagulopathy (international
normalized ratio, 2.1; norm, <1.2; factor V, 28%; norm,
50-150%), acute renal dysfunction (creatinine, 190 μmol/L;
norm, 44-80 μmol/L), most likely due to dehydration, sec-
ondary to vomiting. Therapeutic levels of everolimus (3.3 μg/L)
and tacrolimus (5.1 μg/L) were documented. Tests for viral
infections, including CMV, hepatitis B, C, and E, were
negative; diagnostic tests for HSVand autoimmune hepatitis
were not performed due to low pretest probability. We noted
a low-level Epstein-Barr virus viremia of 2323 IE/mL (detec-
tion limit, <122 IE/mL); however, similar levels have been
noted before on several occasions afterOLT. Ultrasound con-
firmed regular blood supply to the liver. Acetylcystein treat-
ment and encephalopathy prophylaxis with rifaximine and
lactulose were started.
On the second day of admission, the patient suddenly lost
consciousness (Glasgow coma scale, 3), prompting transfer
to the intensive care unit and intubation. Computed tomog-
raphy scan demonstrated extensive liver necrosis and intrace-
rebral bleeding with signs of increased cerebral pressure
(Figure 3). After discussion with her family, therapy was
discontinued and the patient passed away on the same day,
25 days after first administration of nivolumab.
FIGURE 1. Time course for liver function tests and tumor markers before and after nivolumab treatment.
FIGURE2. Liver biopsy 16 days after nivolumab. A, HE staining illus-
trating prominent portal mixed inflammation with interface activity and
isolated hepatocyte necrosis (yellow arrow), cytoplasmatic vacuolization
of the duct epithelium consistent with bile duct damage (red arrow) and
subendothelial lymphocytic inflammation with lifting up of the endothe-
lium compatible with endothelitis (blue arrow); 400. B, Cytokeratin-7
immunohistochemical staining highlighting the influx of inflammatory cells
in the ductal epithelium associated with dysmorphic changes of the bile
duct (magnification, 400).
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Systematic Literature Search
Our systematic literature research for the use of checkpoint
inhibitors in solid organ recipients revealed 25 articles de-
scribing 29 patients, including our presented case (Table 1,
for search strategy see methods). Fourteen of 29 cases were
kidney transplant recipients, 11 cases were liver transplant
recipients, 3 were heart transplant recipients, and 1 patient
had received cornea transplantation.
Graft loss was defined as severe transplant dysfunction
resulting in death in patients after liver or heart transplanta-
tion and hemodialysis in patients after kidney transplantation,
respectively. Because in all patients uncontrolled neoplasiawas
present, retransplantation has not been an option. Acute rejec-
tion was defined graft dysfunction reversed by adequate med-
ical therapy (1 case by Dueland et al).
Rates of graft loss are reported according to the check-
point inhibitor used; patients receiving combination thera-
pies are considered for both drugs.
Nivolumab Treatment in Transplant Patients
Loss of transplant function after nivolumab administration
alone or in combination with ipilimumab15-17,22-29,33,34 oc-
curred in 9 (56%) of 16 cases: graft loss was observed in 4
of 8 cases of kidney transplant recipients, in 3 of 5 cases of liver
transplant recipients and 1 of 2 cases after heart transplanta-
tion. In the case of cornea transplant nivolumab resulted in
graft dysfunction.
Overall cancer response is known in only 11 of the 16 cases:
in 5 cases, progressive disease was described; in 3 cases, regres-
sion was reported; and in 3 cases, stable disease was reported.
Ipilimumab Treatment in Transplant Patients
Loss of transplant function after ipilimumab administration
alone or in combination with nivolumab or pembro-
lizumab11-14,20-24,32 occurred in 4 (36%) of 11 cases:
ipilimumab administration after kidney transplant resulted
in graft loss in 3 out of 6 cases and in liver transplant recipi-
ents in 1 of 4 cases. One heart transplanted patient showed
no rejection after ipilimumab.
Cancer response was reported in all cases: in 7 of 11 cases
progressive disease was described, 1 case showed stable dis-
ease and 3 cases showed tumor regression.
Pembrolizumab Treatment in Transplant Patients
Loss of transplant function after pembrolizumab administra-
tion alone or in combination with ipilimumab14,18,19,28,30,31
occurred in 2 (33%) of 6 cases: pembrolizumab resulted in graft
loss in 2 of 3 cases of kidney transplant recipients but in no re-
jection in 3 cases after liver transplantation.
Cancer response was reported in all cases: in 2 of 6 cases,
progressive disease was described, the remaining 4 cases
showed cancer regression.
A search in VigiBase, the WHO database for pharma-
covigilance, revealed worldwide 9 ICSRs of transplant rejec-
tion after using the checkpoint inhibitor nivolumab between
2015 and August 2017. Transplant rejections of the kidney
(n =6), cornea (n =1), orwithout organ specification (n =2)were
reported. In all cases, nivolumab was labeled as the suspected
drug. In 1 patient, the cytotoxic T-lymphocyte-associated protein
4 (CTLA-4) inhibitor ipilimumabwas coadministered. Fatal out-
comewas documented in 1 female patient with nivolumab treat-
ment for liver carcinoma, who died after transplant rejection.
Further details are not provided in the database.
DISCUSSION
We report a single case of fatal liver failure 3 weeks after
administration of a single dose of nivolumab in a patient with
recurrent HCC 2 years after liver transplantation. Our sys-
tematic literature search identified additional cases with graft
loss after checkpoint inhibitor treatment. Overall, graft loss
or acute rejection, as discussed above, was described in 13
(45%) of 29 cases across all checkpoint inhibitors. For
nivolumab, ipilimumab, and pembrolizumab, rejection rates
of 56%, 36%, and 33%, respectively, were apparent. Loss of
graft function for liver allografts occurred in 3 (37%) of 11
cases, for kidney allografts in 7 (50%) of 14 cases, and heart
allografts in 1 (33%) of 3 cases.
Therefore, our data suggest a severe risk of transplant re-
jection after use of checkpoint inhibitors in patients after
solid organ transplantation. Even though the rates of rejec-
tion were highest with nivolumab, our data do not allow to
compare relative risks of 1 checkpoint inhibitor versus the
other. Furthermore, because our study relies on publication
of case reports, the possibility of publication bias has to be
considered which might result in overestimation or underes-
timation of rejection rates.
The safety of nivolumab or other checkpoint inhibitors in
solid organ recipients has not been established because this
patient population was excluded from relevant clinical
trials.9,10 Formal assessment of causality of nivolumab expo-
sure and fatal liver transplant rejection in our case suggests a
FIGURE 3. Abdominal imaging. A, Contrast-enhanced CTscan demonstrating an enlarged lymph node in the liver hilum (arrow) due to HCC
recurrence 27months after liver transplantation. B, CTscan 9months later with stable lymph node before nivolumab treatment 35months after
liver transplantation. C, CTscan at the day of death 25 days after nivolumab treatment with inhomogeneous hypodense areas in the right he-
patic lobe (arrows) suggestive for parenchymal necrosis. No signs of intrahepatic HCC recurrence. CT, computed tomography.
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“probable” relationship according to the WHO/Council for
International Organizations of Medical Sciences criteria.37
Chronological order of drug exposure and adverse event, exis-
tence of additional caseswith nivolumab treatment and graft re-
jection, pharmacological plausibility, and exclusion of other
nonpharmacological explanations suggest a causal relationship
between nivolumab treatment and graft rejection.
Immune checkpoint inhibitors, including nivolumab and
ipilimumab, revolutionized the treatment of various malig-
nancies. Nivolumab (Opdivo) is a human monoclonal IgG4
antibody which blocks PD-1 receptor on activated T cells, B
cells, natural killer T cells, monocytes, and dendritic cells.38
Programmed cell death protein 1 receptor has 2 ligands,
PD-L1 and PD-L2, which are expressed on tumor cells and
antigen-presenting cells in tumor microenvironment. Binding
of the receptor with its ligand (programmed cell death 1 ligand
1 [PD-L1]) leads to negative regulation of Tcells and lack of T
cell response. Therefore, prevention of PD1 and PD-L1 inter-
action by nivolumab can restore T cell–mediated tumor sup-
pression.26 The mechanism of ipilimumab (Yervoy) is
different from nivolumab because ipilimumab inhibits
CTLA-4 activity. Generally, CTLA-4 modulates T-cell activa-
tion during the initial phase of the immune response, whereas
PD-1 acts during the effector phase.
Induction of immune tolerance of organ-transplanted pa-
tients is crucial after solid organ transplantation. Both PD-1
and CTLA-4 signaling pathways contribute to immune toler-
ance of transplanted organ. PD-L1 expression was proposed
to be the key component of graft tolerance after liver trans-
plantation, because higher expression provides a negative
feedback, creating a protective shield from human T-cell re-
sponses.39 Additionally, PD-1 plays a crucial role in both in-
duction and maintenance of peripheral transplant tolerance
by its ability to alter the balance between pathogenic and reg-
ulatory T cells and it is also involved in T-cell exhaustion—
another emerging mechanism in transplant tolerance.40-44
On the other hand, blocking CTLA-4 in early phases after
transplantation led to transplant rejection in a murine model,
whereas late blockade seems not to affect transplant survival.45,46
Therefore, inhibition of either CTLA-4 or PD-1 after solid
organ transplantation might trigger immune-mediated organ
failure. However, which checkpoint inhibitor would be more
favorable in organ transplant recipients remains unclear. It
also remains unclear whether the time passed after transplan-
tation before checkpoint inhibitor treatment might decrease
the risk for graft loss.
Patients with and without organ failure did not signifi-
cantly differ regarding age, time after transplantation, sex,
graft (liver/kidney/heart) and treatment with nivolumab,
ipilimumab, or pembrolizumab. We noticed a minor trend
for more organ failure in younger patients, which failed to
reach statistical significance.
Our case and the 2 cases described by Friend et al are re-
markable for an extreme severity of liver transplant rejection
leading to rapid transplant failure, nonresponsive to 5 days
high-dose steroids. Hepatic side effects of nivolumab are fre-
quent also in patients without OLT, and immune-mediated
hepatitis with a median time to onset of 3.3 months (range,
6 days to 9 months) is the main hepatic adverse effect of
nivolumab. However, nivolumab-induced hepatitis typically
resolves after discontinuation of treatment47 and usually be-
gins much later than 16 days after administration as in our
patient. It has different histologic features than described in
the liver biopsy in our patient, as it is characterized by an
acute lobular hepatitis with isolated or confluent necrosis
and a predominantly lymphocytic infiltrate. In contrast, in
our case, portal tract inflammation was dominated by a
mixed infiltrate with interface activity, bile duct injury and
endothelitis compatible with acute cellular rejection (RAI:
3/2/2 = 7). Taken together, nivolumab-induced hepatitis
seems an unlikely explanation for liver failure in our patient,
and histological changes favor an acute cellular rejection
(Figure 2).
However, the clinical course in our patient also remains
highly unusual for an acute cellular rejection because this
complication only infrequently occurs more than 1 year after
transplantation, especially in patients with good therapeutic
adherence and no prior history of cellular rejection. Further,
acute cellular rejection typically responds to steroid treatment
and virtually never progresses to fulminant liver failure. It
therefore seems probable that nivolumab exposure and PD-1
inhibition had induced a cellular rejection of unusual severity,
leading to fulminant liver transplant failure. However, the un-
derlying immunological mechanisms are unknown.
Our patient ultimately succumbed to fatal intracranial
bleeding. Whether this complication is related to coagulopa-
thy associated with liver failure remains unclear because per-
mission to perform autopsy in this patient was not granted.
Management of checkpoint inhibitor-associated solid allo-
graft failure is unclear. Acute graft rejection resolves upon
high-dose steroid treatment in 70% to 80% of all cases.48
However, neither in our patient nor in those patients de-
scribed by Friend et al or in other cases identified in our liter-
ature search did high-dose steroid treatment result in clinical
improvement. Rapid clinical deterioration in our patient pre-
cluded alternative treatment options, such as infliximab,49
antithymoglobuline,50 or cyclosporine. Plasmapheresis was
not used in the cases described involving organ failure after
checkpoint inhibitor treatment. Plasmapheresis has been
used for treatment of acute humoral rejection after OLT51
but it will likely not stop the T cell–mediated immune rejec-
tion after checkpoint inhibitor treatment. However, plasma-
pheresis would remove the checkpoint inhibitor from the
circulation, which might potentially be beneficial. Taken to-
gether, nomedical treatment for graft failure after checkpoint
inhibitor treatment has been identified.
CONCLUSIONS
Solid allograft failure is a severe or catastrophic complica-
tion after checkpoint inhibitor treatment. No medical treat-
ment options have been identified. Our case and several
published cases suggest a 36% to 54% risk of graft loss on
checkpoint inhibitor treatment.
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